Tetrahydrohyperforin decreases cholinergic markers associated with amyloid-β plaques, 4-hydroxynonenal formation, and caspase-3 activation in aβpp/ps1 mice

Journal of Alzheimer's Disease

Volumn 36, Issue 1, 2013, Pages 99-118

  Carvajal, Francisco J ^a   Zolezzi, Juan M ^a   Tapia Rojas, Cheril ^a   Godoy, Juan A ^a   Inestrosa, Nibaldo C ^a,b  

^a Center for Advanced Studies in Ecology and Biodiversity   (Chile)

^b PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

4 hydroxynonenal adducts; acetylcholinesterase; Alzheimer's disease; A AChE interactions; A PP PS1 transgenic mice; caspase 3; tetrahydrohyperforin; 7 nAChR

Indexed keywords

4 HYDROXYNONENAL; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER; BUNGAROTOXIN RECEPTOR; CASPASE 3; CHOLINERGIC RECEPTOR; HYPERFORIN; TETRAHYDROHYPERFORIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; HIPPOCAMPUS; IMMUNOBLOTTING; IN VITRO STUDY; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPATIAL MEMORY; TISSUE CULTURE; TRANSGENIC MOUSE;

EID: 84878834027     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-130230     Document Type: Article

References (77)

1. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E (2011) Alzheimer's disease. Lancet 377, 1019-1031.
2. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT (2011) Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Biol 3, a006189.
3. Bonda DJ, Castellani RJ, Zhu X, Nunomura A, Lee HG, Perry G, Smith MA (2011) A novel perspective on tau in Alzheimer's disease. Curr Alzheimer Res 8, 639-642.
4. Castellani RJ, Nunomura A, Lee HG, Perry G, Smith MA (2008) Phosphorylated tau: Toxic, protective, or none of above. J Alzhemers Dis 14, 377-383.
5. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci 24, 1121-1159.
6. Li S, Shankar GM, Selkoe DJ (2010) How do soluble oligomers of amyloid beta-protein impair hippocampal synaptic plasticity? Front Cell Neurosci 4, 5.
7. Bartus RT(2000)Onneurodegenerative diseases, models, and treatment strategies: Lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163, 495-529.
8. Dumas JA, Newhouse PA (2011) The cholinergic hypothesis of cognitive aging revisited again: Cholinergic functional compensation. Pharmacol Biochem Behav 99, 254-261.
9. Potter PE, Rauschkolb OK, Pandya Yoga, Sue IL, Sabbagh MN, Walker DG, Beach TG (2011) Pre-and postsynaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease. Acta Neuropathol 122, 49-60.
10. DeKosky ST, Ikonomovic MD, Styren SD, Beckett L, Wisniewski S, Bennett DA, Cochran EJ, Kordower JH, Mufson EJ (2002) Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol 51, 145-155.
11. Bissette G, Seidler FJ, Nemeroff CB, Slotkin TA (1996) High affinity choline transporter status in Alzheimer's disease tissue from rapid autopsy. Ann N Y Acad Sci 777, 197-204.
12. Dinamarca MC, Rios JA, Inestrosa NC (2012) Postsynaptic receptors for amyloid-oligomers as mediators of neuronal damage in Alzheimer's disease. Front Physiol 3, 464.
13. Gotti C, Moretti M, Bohr I, Ziabreva I, Vailati S, Longhi R, Riganti L, Gaimarri A, Mckeith IG, Perry RH, Aarland D, Larsen JP, Sher E, Beattie R, Clementi, Court JA(2006) Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. Neurobiol Dis 23, 481-489.
14. Ikonomovic MD,Wecker L, Abrahamson EE,Wuu J, Counts SE, Ginsberg SD, Mufson EJ, DeKosky ST (2009) Cortical-7 nicotinic acetylcholine receptor and-amyloid levels in early Alzheimer disease. Arch Neurol 66, 646-651.
15. Inestrosa NC, Dinamarca MC, Alvarez A (2008) Amyloidcholinesterase interactions. Implications for Alzheimer's disease. FEBS J 275, 625-632.
16. Geula C, Mesulam MM (1989) Cortical cholinergic fibers in aging and Alzheimer's disease: A morphometric study. Neuroscience 33, 469-481.
17. Beach TG, Kuo YM, Spiegel K, Emmerling MR, Sue LI, Kokjohn K, Roher A (2000) The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. J Neuropathol Exp Neurol 59, 308-313.
18. Atack JR, Perry EK, Bonham JR, Perry RH, Tomlinson BE, Blessed G, Fairbairn A (1983) Molecular forms of acetylcholinesterase in senile dementia of Alzheimer type: Selective loss of the intermediate (10S) form. Neurosci Lett 40, 199-204.
19. Kalaria RN, Kroon SN, Grahovac I, Perry G (1992) Acetylcholinesterase and its association with heperan sulphate proteoglycans in cortical amyloid deposits of Alzheimer's disease. Neuroscience 51, 177-184.
20. Saez-Valero J, Sberna G, McLean CA, Small DH (1999) Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. J Neurochem 72, 1600-1608.
21. Geula C, Mesulam MM (1995) Cholinesterases and the pathology of Alzheimer disease. Alzheimer Dis Assoc Disord 9(Suppl 2), 23-28.
22. Inestrosa NC, Alvarez A, Perez CA, Moreno RD, Vicente M, Linker C, Casanueva OI, Soto C, Garrido J (1996) Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: Possible role of the peripheral site of the enzyme. Neuron 16, 881-891.
23. Alvarez A, Opazo C, Alarcon R, Garrido J, Inestrosa NC (1997) Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. J Mol Biol 272, 348-361.
24. Tago H, McGeer PL, McGeer EG (1987) Acetylcholinesterase fibers and the development of senile plaques. Brain Res 406, 363-369.
25. Munoz FJ, Inestrosa NC (1999) Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes. FEBS Lett 450, 205-209.
26. Carvajal FJ, Inestrosa NC (2011) Interactions of AChE with A-aggregates in Alzheimer's brain: Therapeutic relevance of IDN 5706. Front Mol Neurosci 4, 19.
27. Dinamarca MC, Sagal JP, Quintanilla RA, Godoy JA, Arrazola MS, Inestrosa NC (2010) Amyloid-beta-Acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease. Mol Neurodegener 5, 4.
28. Ji C, Amarnath V, Pietenpol JA, Marnett LJ (2001) 4-hydroxynonenal induces apoptosis via caspase-3 activation and cytochrome c release. Chem Res Toxicol 14, 1090-1096.
29. Miranda S, Opazo C, Larrondo LF, Muñoz FJ, Ruiz F, Leighton F, InestrosaNC(2000) The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog Neurobiol 62, 633-648.
30. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthoudakis S, Zamboni RJ, Roy S, Nicholson DW (1999) Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97, 395-406.
31. Hyman BT (2011) Caspase activation without apoptosis: Insight into Abeta initiation of neurodegeneration. Nat Neurosci 14, 5-6.
32. D'Amelio M, Cavallucci V, Middei S, Marchetti C, Pacioni S, Ferri A, Diamantini A, De Zio D, Carrara P, Battistini L, Moreno S, Bacci A, Ammassari-Teule M, Marie H, Cecconi F (2011) Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer's disease. Nat Neurosci 14, 69-76.
33. KlusaV, Germane S, Noldner M, Chatterjee SS (2001) Hypericum extract and hyperforin: Memory-enhancing properties in rodents. Pharmacopsychiatry 34(Suppl 1), S61-S69.
34. Griffith TN, Varela-Nallar L, Dinamarca MC, Inestrosa NC (2010) Neurobiological effects of Hyperforin and its potential in Alzheimer's disease therapy. Curr Med Chem 17, 391-406.
35. Dinamarca MC, Cerpa W, Garrido J, Hancke JL, Inestrosa NC (2006) Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer's amyloid-beta-deposits. Mol Psychiatry 11, 1032-1048.
36. Cerpa W, Hancke JL, Morazzoni P, Bombardelli E, Riva A, Marin PP, Inestrosa NC (2010) The hyperforin derivative IDN5706 occludes spatial memory impairments and neuropathological changes in a double transgenic Alzheimer's mouse model. Curr Alzheimer Res 7, 126-133.
37. Dinamarca MC, Arrazola M, Toledo E, Cerpa WF, Hancke J, Inestrosa NC (2008) Release of acetylcholinesterase (AChE) from beta-amyloid plaques assemblies improves the spatial memory impairments in APP-transgenic mice. Chem Biol Interact 175, 142-149.
38. Inestrosa NC, Tapia-Rojas C, Griffith TN, Carvajal FJ, Benito MJ, Rivera-Dictter A, Alvarez AR, Serrano FG, Hancke JL, Burgos PV, Parodi J, Varela-Nallar L (2011) Tetrahydrohyperforin prevents cognitive deficit, A-deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1-E9 model of Alzheimer's disease: A possible effect on APP processing. Transl Psychiatry 1, e20.
39. Ellman GL, Courtney KD, Andres V, Jr. Feather-Stone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7, 88-95.
40. Bailey JA, Ray B, Greig NH, Lahiri DK (2011) Rivastigmine lowers A-and increases sAPP-levels, which parallel elevated synaptic markers and metabolic activity in degenerating primary rat neurons. Plos ONE 6, e21954.
41. Inestrosa NC, Reiness CG, Reichardt LF, Hall ZW (1981) Cellular localization of the molecular forms of acetylcholinesterase in rat pheochromocytoma PC12 cells treated with nerve growth factor. J Neurosci 1, 1260-1267.
42. Alvarez A, Alarcon R, Opazo C, Campos EO, Munoz FJ, Calderon FH, Dajas F, Gentry MK, Doctor BP, De Mello FG, Inestrosa NC (1998) Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. J Neurosci 18, 3213-3223.
43. Chacon MA, Barria MI, Soto C, Inestrosa NC (2004) Betasheet breaker peptide prevents Abeta-induced spatial memory impairments with partial reduction of amyloid deposits. Mol Psychiatry 9, 953-961.
44. Toledo EM, Inestrosa NC (2010) Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol Psychiatry 15, 272-285, 228.
45. Tago H, Kimura H, Maeda T (1986) Visualization of detailed acetylcholinesterase fiber and neuron staining in rat brain by a sensitive histochemical procedure. J Histochem Cytochem 34, 1431-1438.
46. Cancino GI, Toledo EM, Leal NR, Hernandez DE, Yevenes LF, Inestrosa NC, Alvarez AR (2008) STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits. Brain 131, 2425-2442.
47. Bussiere T, Bard F, Barbour R, Grajeda H, Guido T, Khan K, Schenk D, Games D, Seubert P, Buttini M (2004) Morphological characterization of Thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive Abeta immunotherapy on their clearance. Am J Pathol 165, 987-995.
48. Garcia-Ayllon MS, Small DH, Avila J, Saez-Valero J (2011) Revisiting the role of acetylcholinesterase in Alzheimer's disease: Cross-talk with p-tau and beta-amyloid. Front Mol Neurosci 4, 22.
49. Bednar I, Paterson D, Marutle A, Pham TM,Svedberg M, Hellstrom-Lindahl E, Mousavi M, Court J, Morris C, Perry E, Mohammed A, Zhang X, Nordberg A (2002) Selective nicotinic receptor consequences in APP(swe) transgenic mice. Mol Cell Neurosci 20, 354-365.
50. Dineley KT (2007) Beta-amyloid peptide-nicotinic acetylcholine receptor interaction: The two faces of health and disease. Front Biosci 12, 5030-5038.
51. Marutle A, Unger C, Hellström-Lindahl E, Wang J, Puoliv äli J, Tanila H, Nordberg A, Zhang X (2002) Elevated levels of Abeta1-40 and Abeta1-42 do not alter the binding sites of nicotinic receptor subtypes in the brain of APPswe and PS1 double transgenic mice. Neurosci Lett 328, 269-272.
52. Sparks DL, Beach TG, Lukas RJ (1998) Immunohistochemical localization of nicotinic beta2 and alpha4 receptor subunits in normal human brain and individuals with Lewy body and Alzheimer's disease: Preliminary observations. Neurosci Lett 256, 151-154.
53. Teaktong T, Graham AJ, Court JA, Perry RH, Jaros E, Johnson M, Hall R, Perry EK (2004) Nicotinic acetylcholine receptor immunohistochemistry in Alzheimer's disease and dementia with Lewy bodies: Differential neuronal and astroglial pathology. J Neurol Sci 225, 39-49.
54. Garcia-Alloza M, Robbins EM, Zhang-Nunes SX, Purcell SM, Betensky RA, Raju S, Prada C, Greenberg SM, Bacskai BJ, Frosch MP(2006) Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24, 516-524.
55. Rozio M, Fracasso C, Riva A, Morazzoni P, Caccia S (2005) High-performance liquid chromatography measurement of hyperforin and its reduced derivatives in rodent plasma. J Chromatogr B Analyt Technol Biomed Life Sci 816, 21-27.
56. Yan P, Bero AW, Cirrito JR, Xiao Q, Hu X,Wang Y, Gonzales E, Holtzman DM, Lee JM (2009) Characterizing the appearance and growth of amyloid plaques in APP/PS1. J Neurosci 29, 10706-10714.
57. Darvesh S, Cash MK, Reid GA,Martin E, Mitnitski A, Geula C (2012) Butyrylcholinesterase is associated with b-amyloid plaques in the transgenic APPSWE/PSEN1dE9 mouse model of Alzheimer disease. J Neuropathol Exp Neurol 71, 2-14.
58. Inestrosa NC, Carvajal FC, Zolezzi JM, Tapia-Rojas C, Serrano F, Karmelic EM, Toro A, Toro J, Santos MJ (2013) Peroxisome proliferators reduce the spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer's disease. J Alzheimers Dis 33, 941-959.
59. Schliebs R, Arendt T (2006) The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm 113, 1625-1644.
60. Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF (2009) Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci 29, 8805-8815.
61. Buckingham SD, Jones AK, Brown LA, Sattelle DB (2009) Nicotinic acetylcholine receptor signalling: Roles in Alzheimer's disease and amyloid neuroprotection. Pharmacol Rev 61, 39-61.
62. Hernandez CM, Kayed R, Zheng H, Sweatt JD, Dineley KT (2010) Loss of alpha7 nicotinic receptors enhances betaamyloid oligomer accumulation, exacerbating early-stage cognitive decline and septohippocampal pathology in a mouse model of Alzheimer's disease. J Neurosci 30, 2442-2453.
63. Li SF, Wu MN, Wang XH, Yuan L, Yang D, Qi JS (2011) Requirement of-7 nicotinic acetylcholine receptors for amyloid -protein-induced depression of hippocampal long-term potentiation in CA1 region of rats in vivo. Synapse 65, 1136-1143.
64. Belluti F, Rampa A, Piazzi L, Bisi A, Gobbi S, Bartolini M, Andrisano V, Cavalli A, Recanatini M, Valenti P (2005) Cholinesterase inhibitors: Xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation. J Med Chem 48, 4444-4456.
65. Bartolini M, Bertucci C, Cavrini V, Andrisano V (2003) beta-Amyloid aggregation induced by human acetylcholinesterase: Inhibition studies. Biochem Pharmacol 65, 407-416.
66. Colombres M, Sagal JP, Inestrosa NC (2004) An overview of the current and novel drugs for Alzheimer's disease with particular reference to anti-cholinesterase compounds. Curr Pharm Des 10, 3121-3130.
67. Munoz-Torrero D (2008) Acetylcholinesterase inhibitors as disease-modifying therapies for Alzheimer's disease. Curr Med Chem 15, 2433-2455.
68. Munoz-Torrero D, Camps P (2006) Dimeric and hybrid anti-Alzheimer drug candidates. Curr Med Chem 13, 399-422.
69. Martinez A, Lahiri DK, Giacobini E, Greig NH (2009) Advances in Alzheimer therapy: Understanding pharmacological approaches to the disease. Curr Alzheimer Res 6, 83-85.
70. Zhu Y, Xiao K, Ma L, Xiong B, Fu Y, Yu H, Wang W, Wang X, Hu D, Peng H, Li J, Gong Q, Chai Q, Tang X, Zhang H, Li J, Shen J (2009) Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase. Bioorg Med Chem 17, 1600-1613.
71. Viayna E, Gómez T, Galdeano C, Ramírez L, Ratia M, Badia A, Clos MV, Verdaguer E, Junyent F, Camins A, Pallás M, Bartolini M, Mancini F, Andrisano V, Arce MP, Rodríguez-Franco MI, Bidon-Chanal A, Luque FJ, Camps P, Muñoz-Torrero D (2010) Novel huprine derivatives with inhibitory activity toward beta-amyloid aggregation and formation as disease-modifying anti-Alzheimer drug candidates. ChemMedChem 5, 1855-1870.
72. Dumont M, Beal MF (2011) Neuroprotective strategies involving ROS in Alzheimer's disease. Free Radic Biol Med 51, 1014-1026.
73. Lee HP, Zhu X, Casadesus G, Castellani RJ, Nunomura A, Smith MA, Lee HG, Perry G (2010) Antioxidant approaches for the treatment of Alzheimer's disease. Expert Rev Neurother 10, 1201-1208.
74. Smith MA, Perry G, Richey PL, Sayre LM, Anderson VE, Beal MF, Kowall N (1996) Oxidative damage in Alzheimer's disease. Nature 382, 120-121.
75. Mark RJ, Lovell MA, Markesbery WR, Uchida K, Mattson MP (1997) A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide. J Neurochem 68, 255-264.
76. Williams TI, Lynn BC, Markesbery WR, Lovell MA (2006) Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. Neurobiol Aging 27, 1094-1099.
77. Siegel SJ, Bieschke J, Powers ET,Kelly JW(2007) The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 46, 1503-1510.